Aprizo 20 Tablet

About Aprizo 20 Tablet

Aprizo 20 is a tablet containing apremilast 20 mg, a disease-modifying antirheumatic drug (DMARD). It is used in adults with active psoriatic arthritis and moderate to severe plaque psoriasis.

There are 5 brands of Apremilast listed in Bangladesh.

What is Aprizo 20 Tablet?

Aprizo 20 is a tablet made by Nuvista Pharma Ltd that contains apremilast 20 mg. Apremilast belongs to a group of medicines called disease-modifying antirheumatic drugs (DMARDs). It works by blocking an enzyme inside inflammatory cells, which helps reduce the production of several substances that drive inflammation. Doctors prescribe it for adults with active psoriatic arthritis and for adults with moderate to severe plaque psoriasis who are suitable for phototherapy or systemic therapy. The dose and the course are decided by the doctor, and the doctor may adjust how the medicine is started.

Uses of Aprizo 20

Aprizo 20 is used for adults with active psoriatic arthritis, a condition where joints become painful and swollen alongside skin problems. It is also used for adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. It is not a painkiller and does not give quick relief; it is a longer-term treatment for these inflammatory conditions.

How to use Aprizo 20

Take Aprizo 20 exactly as your doctor tells you. It can be taken with or without food. Doctors often start this medicine at a lower strength and build up over the first few days to reduce stomach upset, so follow your own schedule closely. Do not change the dose or stop on your own. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Aprizo 20

The most common side effects are nausea, diarrhoea and headache. Less frequent ones include vomiting, upper respiratory tract infection, sore throat, abdominal pain, indigestion, reflux, fatigue, reduced appetite, cough, rash, insomnia and hypersensitivity. Contact your doctor promptly if you notice new or worsening low mood, thoughts of self-harm or other mood changes, or if side effects bother you or do not settle.

Safety and precautions

Tell your doctor before starting Aprizo 20 if you have ever had depression or mood problems, because this medicine can worsen such symptoms and your doctor will want to monitor you. Ask your doctor first if you have liver or kidney problems, low body weight, or are taking other medicines, including rifampin, phenobarbital, carbamazepine or phenytoin, as these can affect treatment. It is in pregnancy category C, and it is not known whether it passes into human breast milk. Ask your doctor before use in pregnancy or breastfeeding.

Frequently asked questions

What is Aprizo 20 used for and what kind of medicine is it?

It is a disease-modifying antirheumatic drug (DMARD) containing apremilast. Doctors use it for adults with active psoriatic arthritis and for adults with moderate to severe plaque psoriasis who are suitable for phototherapy or systemic therapy. The doctor decides the dose and course.

What side effects should I watch for with Aprizo 20?

Common side effects include nausea, diarrhoea and headache. Less common ones include vomiting, abdominal pain, indigestion, fatigue, reduced appetite, cough, rash and insomnia. Call your doctor if you notice new or worsening low mood, thoughts of self-harm or other mood changes, or if side effects are troublesome.

Is Aprizo 20 safe in pregnancy or breastfeeding?

It is in pregnancy category C, and it is not known whether apremilast passes into human breast milk. Do not start or continue this medicine in pregnancy or while breastfeeding without talking to your doctor, who will weigh the risks and benefits for you.

Can I take Aprizo 20 with other medicines?

Some medicines can lower the levels of apremilast in the body. These include rifampin, phenobarbital, carbamazepine and phenytoin, and the combination is not recommended. Tell your doctor and pharmacist about all medicines you take, including herbal products, before starting treatment.

Indications

Apremilast is indicated for the treatment of adult patients with active psoriatic arthritis and moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Pharmacology

Apremilast is a novel, orally available small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4). PDE-4 is a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase that is predominantly located in inflammatory cells. By inhibiting PDE-4, apremilast increases intracellular levels of cAMP and thereby inhibits the production of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2), interferon-gamma, leukotrienes, and nitric oxide synthase. By targeting a central component of the inflammatory signaling cascade rather than a single inflammatory marker, PDE-4 inhibition may restore the homeostatic balance between pro- and anti-inflammatory signalling.

Dosage & Administration

The recommended initial dosage titration of Apremilast from Day 1 to Day 5 is shown below. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy. Apremilast can be administered without regard to meals.

Day 1: 10 mg in morning
Day 2: 10 mg in morning and 10 mg in evening
Day 3: 10 mg in morning and 20 mg in evening
Day 4: 20 mg in morning and 20 mg in evening
Day 5: 20 mg in morning and 30 mg in evening
Day 6: 30 mg twice daily

Dosage adjustment in patients with severe renal impairment. Apremilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment. For initial dosage titration, it is recommended that Apremilast be titrated using only the morning schedule and the evening doses be skipped.

Interaction

Co-administration of strong cytochrome P450 enzyme inducer Rifampin resulted in a reduction of systemic exposure of Apremilast.Therefore.the use of cytochrome P450 enzyme inducers (e.g. Rifampin, Phenobarbital,Carbamazepine, Phenytoin) with Apremilast is not recommended.

Contraindications

Apremilast is contraindicated in patients with a known hypersensitivity to Apremilast or to any of the excipients in the formulation.

Side Effects

The most frequently occurring side effects of Apremilast are nausea, diarrhea and headache. Other less frequent side effects are upper respiratory tract infection, vomiting, naospharyngitis, abdominal pain, hypersensitivity, gastroesophageal reflux disease, dyspepsia, fatigue, decrease appetite, cough, rash, insomnia.

Pregnancy & Lactation

Pregnancy Category C. It is not known whether Apremilast or its metabolites are present in human milk; however, Apremilast was detected in milk of lactating mice. Caution should be exercised when Apremilast is administered to a nursing woman.

Precautions & Warnings

Treatment with Apremilast is associated with an increase in adverse reactions of depression. Patients, their caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Apremilast if such events occur.

During the controlled period of the studies in psoriatic arthritis, weight decrease between 5-10% of body weight was reported in 10% of subjects treated with Apremilast 30 mg twice daily compared to 3.3% treated with placebo.

Storage Conditions

Store at cool & dry place, protected from light & moisture. Keep the medicine out of the reach of children.

Alternative brands of Apremilast

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.